Search Results
Results found for "Luke Pattison"
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
Assay sensitivity is like adjusting the brightness on a microscope—set it right, and hidden details jump Think of it this way: most receptors behave like switches—they stay off until flipped. But some leak current, like a switch glowing faintly in the dark. Model patient-like pathophysiological states (e.g., reduced receptor expression in heart failure).
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
Those courses didn’t feel like career-defining moments at the time — just requirements to pass. Hodson made what seemed like a purely tactical decision: choose a research elective to focus on exams They start with people you actually like working with .
- Is Your Agonist Really “Working”—Or Are You Just Seeing What Your System Allows?
. 👉 Dive into Terry’s Vault and see agonism like never before Unlock "Agonism & Sensitivity" now
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. In reality, the FDA acts more like a systems-level risk assessor . indication selection to study design, should be filtered through the question: “What would this look like
- Innovative Data-Driven Solutions: The pHSense Revolution
Build or adopt assays that can evolve with your questions—like pHSense.” What’s Next? “It’s like a funnel,” Trinquet explains. GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr.
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid But those failures are where new paths emerge, often leading to transformative tools like the IP1 assay GPCR X Revvity Collaboration ⸻ Want more like this? 👉 Join the Dr.
- Pharmacology Isn't What You Think—It's So Much More
Ever wondered why a drug behaves like a miracle in one tissue and a dud in another?
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
re early in your career or pushing the edge of MoA design, weekly lesson help you apply key concepts like GPCR mutations in cancer show both driver-like patterns and high redundancy, prompting a call for multiomics
- Adhesion GPCR Consortium Newsletter - May 2024
AB: The next workshop will likely bring together some of the hottest adhesion GPCR research going on community, added to the fact that this will all take place for the first time in a developing country like The food: While in Mexico, eat like one. The diversity is humongous. What mariachi song are you most likely to shout along to at 3 AM? song: I typically do not sing to these since they are dear to Mexican childhood memories, and I feel like
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules) Among the top-ranked compounds, 59 fragments and 59 lead-like compounds were selected for experimental Of these, four fragment- and seven lead-like compounds were confirmed to bind to the allosteric site The results demonstrate that virtual screens of fragment- and lead-like chemical libraries have complementary
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules) Among the top-ranked compounds, 59 fragments and 59 lead-like compounds were selected for experimental Of these, four fragment- and seven lead-like compounds were confirmed to bind to the allosteric site The results demonstrate that virtual screens of fragment- and lead-like chemical libraries have complementary
- From Failed Experiments to Predictive GPCR Models
Inspired by news stories about breakthroughs like the cloning of Dolly the sheep and genetically modified of his early projects involved the A2A adenosine receptor, a GPCR with known relevance in diseases like AI and the Future of GPCR Modeling Carlsson is excited by the potential of tools like AlphaFold and Looking for more insights like this? The Dr.
- The Five Traps of Ignoring Kinetics
Think of it like catching a train: two passengers have tickets (affinity), but only the one who sprints It’s like calculating a runner’s pace and realizing they’d have to break the sound barrier to make the It’s like waiting for popcorn: at first, nothing happens, then suddenly the bag explodes with pops.
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Sharing the round table discussion with these excellent scientists felt like a dream come true, and Maria given targeted both traditional GPCRs such as the serotoninergic receptor 5HT1A, but also newer targets like
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
Moments like these helped him own his identity as a scientist.
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
Traditional methods like radioligand binding assays or calcium flux measurements have significant drawbacks They can be combined with second generation acceptors like d2, as well as brighter donors, further increasing On top of that, smaller acceptors like d2 reduce steric hindrance, making them more efficient.
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
But Sokhom Pin stayed loyal to GPCRs , even when big pharma turned its gaze to other targets like kinases
- From Multiplex to Models: Scaling Up GPCR Discovery in the Post-Silo Era
students and visiting scientists are already expanding this work, bringing in computational layers like
- Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs
GPCRs in Disease Sakmar highlights how endothelial cells, which express a wide array of GPCRs, are likely
- The Hidden Cost of Ambition in Biotech Leadership
What feels like momentum can quietly become dilution. More programs. Broader roadmaps. What Strategic Discipline Actually Looks Like in Practice Strategic discipline does not mean shrinking If it does not clearly move the company toward the next decisive milestone, it likely dilutes attention
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
One of the identified TAAR1 agonists demonstrated promising antipsychotic-like effects in rodent models generalize this accuracy to synthetic compounds, limiting its utility in drug discovery involving novel drug-like
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! ❄ Dec 2 - 8, 2024
It's starting to look a lot like Christmas at Dr. GPCR! VI drives arrestin-independent internalization and signaling of GPCRs Corticotropin-releasing factor-like learning GPCRs in Oncology and Immunology Short-chain fatty acids and cancer The path of GPR87: from a P2Y-like
- From Pipettes to Platforms: The Evolution of GPCR Research
Every step felt like it could make or break the result, The pace and precision of GPCR research today Like many, it was a mix of opportunity, timing, and the courage to say yes before everything was figured
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
In This Session, You’ll Gain: ✅ Modeling tools to understand how restricted diffusion in tissues like And when receptors are dense (like GPCRs on membranes), this rebinding hits the collisional limit , where
- 📰 GPCR Weekly News, October 30 to November 4, 2023
Binders, Drugs, and more Cloning and deorphanization of three inotocin (insect oxytocin/vasopressin-like & Updates in GPCR Research Mining the ZINC database of natural products for specific, testosterone-like in serotonin GPCRs Study of G protein-coupled receptors dimerization: From bivalent ligands to drug-like Function - Consequences of subcellular cAMP signaling revealed AI Predicts How GPCRs Respond to Drug-Like
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
acquire three-dimensional image stacks, facilitating the reconstruction of GPCR distribution in tissue-like A High Content Screening focused microscope that has a confocal-like mode as well.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
theoretical—Kenakin shows data from risperidone, comparing offset rates in open compartments vs. restricted ones like key scaffold properties that determine success, offering practical tips for design teams to tune drug-like
- Newly launched antibody libraries put hard-to-drug targets within reach
Antibody developers are increasingly utilising antibody libraries to derive high-quality, drug-like biologics The drugs also target relatively low-hanging fruit: like cytokines or tyrosine kinase receptors. To target hard-to-drug targets like G protein-coupled receptors (GPCRs), more libraries, including better
- ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the...
harbored in the ADGLR3-hormone receptor domain (HRM, a common extracellular domain of the secretin-like showed that functional mutations in the ADGLR3 gene disrupt the standard and wild ADGRL3 structure, most likely
- The Hidden Burn: How Internal Misalignment Drains Your Biotech’s Runway
. 👉 We’re talking about the type of quiet misalignment that appears to be progress but feels like confusion Realignment as a Growth Lever, Not Just a Fix 👉 Most founders treat alignment like a hygiene issue. But because it ensures everyone is solving the same problem. ✅ If your biotech startup feels like it’
























